Monthly Archives: October 2017

Lowering the fraud of online ads

KEY TAKEAWAY: Online ad fraud is shaking the online advertising industry at a time when advertisers are pouring a ton of money into the channel.  However, what’s been overlooked is that the creative for most online ads is horrible. If pharma marketers want to lower the risk of online ad fraud and improve metrics they have to do two things: ditch programmatic and improve online ad creative. Continue reading

With so much online fraud where will pharma money go?

KEY TAKEAWAY: According to Fierce Pharma “Outcome Health went into crisis communications mode after a Wall Street Journal article last week said the fast-growing pharma services company had misled its advertisers. Within hours, the company posted a letter to clients—on its website and social media—outlining in detail how it was addressing the problem”.  Just pile on the fraud! Continue reading

Celgene proves pharma greed is alive and well

KEY TAKEAWAY: A report found that 27 percent of cancer survivors or close relatives of a cancer patient said they’d skipped doctor visits or taken other steps to reduce health costs.  Yet, according to Fierce Pharma  “defying critics in Congress and elsewhere, Celgene hiked the list prices of key cancer meds Revlimid and Pomalyst by 9% this month, taking their cumulative increases for the year to nearly double the range that many Big Pharma peers have pledged to avoid”.  Continue reading